Barrow Robert
Chief Executive Officer
Barrow Robert has filed 10 SEC Form 4 filings (11 transaction rows) across 2 companies, including DFTX, MNMD, with disclosures dating back to 2025. 9 of those filings fall inside the rolling window. Most recent filing: Sep 30, 2026.
On the most recent filing, Barrow Robert is listed as Chief Executive Officer at Definium Therapeutics, Inc. Inside the rolling window, Barrow Robert reported no open-market purchases and 5 open-market sales totaling $4.0M in DFTX and MNMD. The largest disclosed transaction in the window is a sale of 29,208 DFTX shares on Jun 25, 2026, worth $1.3M.
Companies traded
Other insiders at DFTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.0M
reported sales (SEC code S)
Companies
2
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 25, 2025 | MNMD | Sale | $252K |
Frequently asked questions
How many SEC Form 4 filings has Barrow Robert made?
Barrow Robert has filed 10 SEC Form 4 filings (11 transaction rows) across 2 companies, including DFTX, MNMD since 2025.
Which companies does Barrow Robert trade?
Barrow Robert has filed SEC Form 4 disclosures for 2 companies, including DFTX, MNMD.
When was Barrow Robert's most recent SEC Form 4 filing?
Barrow Robert's most recent SEC Form 4 filing on Tracefour is dated Sep 30, 2026.
What is Barrow Robert's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Barrow Robert is listed as Chief Executive Officer.
What is Barrow Robert's total buy and sell value in the current window?
Inside the rolling retention window, Barrow Robert bought $0 and sold $4.0M based on SEC Form 4 filings.
What was Barrow Robert's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 29,208 DFTX shares on 2026-06-25, worth $1.3M, per SEC Form 4 filings.